Let me share a post about a trading opportunity that I put up today on my paid sites.
Yes, that’s sites. Plural. I’ve been busy building a second site, JugglingWithKnives.com, that parallels the focus of my book Juggling With Knives on volatility. If you want everything I write on every topic, my paid $199 site, JubakAM.com is still the place to go. If you want everything that appears on this free site plus my posts on volatility and access to a new Volatility Portfolio (which also appears on JubakAM.com, I’d note) that I’ve just started, subscribe to that site for $79 a year. (Or buy a copy of my book and read it until you find the secret code that will let you get on JugglingWithKnives.com for free for a year.)
All of which brings me to today’s post.
We’re right at the beginning of the medical conference season, which gives biotechs with any news at all a big showcase for the promising new drugs in their pipelines. The American College of Cardiology’s annual conference runs from March 13 to 15 in Washington, D.C. The annual meeting of the American Association for Cancer Research begins on April 1 and extends to April 5, also in Washington. The American Academy of Neurology meets from April 22 to April 28 in Boston.
How big a showcase can one of these conferences be for a biotech company?
Here’s the opportunity for Incyte at the American Association for Cancer Research meeting. Incyte will present 20 abstracts from its R&D portfolio at the conference including a clinical presentation of the dose-escalation phase of the ongoing trial of its FGFR 1/2/3 inhibitor, and preclinical data from inhibitor programs targeting PI3Kd, LSDa, JAK1, BRD/BET and IFFR4, as well as from its epacadostat and immuno-oncology programs.
Companies don’t go to these conferences to announce bad news and failing tests. So these meetings can provide a big dose of market-moving good news.
The rest of the post looks at the odds that conference season will give a significant boost after the recent dip in the biotech sector to Incyte (INCY), Ionis (IONS), Acadia (ACAD), Nektar (NKTR) and the Medicines Company (MDCO.) It also explains why I added Nektar Therapeutics to my new Volatility Portfolio.
Anyway that’s what I’m working on at my subscription sites, JugglingWithKnives.com and JubakAM.com.
I think there’s some value to you in passing on the direction of my thinking about the market on those sites. Hope so anyway.
Of course, there’s an ulterior motive to sharing this with you: If you decide that you’d like more of my thoughts on the market in my JugglingWithKnives.com or JubakAM.com posts, I’m hoping that you’ll subscribe to my sites for either $79 or $199.